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Localization of endothelin peptides in human kidney
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Localization of endothelin peptides in human kidney. We investigated
the synthesis and localization of endothelin isoforms in the human kidney
using the reverse-transcriptase polymerase chain reaction (RT-PCR) and
immunocytochemistry. PCR products corresponding to the expected size
for mRNA encoding ET-1, ET-2 and ET-3 were found in homogenates of
renal medulla, cortex and vessels from each of five individuals. Using four
rabbit polyclonal antibodies to assess the distribution of mature ET, Big
ET-1, Big ET-2 and Big ET-3 immunoreactivity in the human kidney,
mature IR ET localized to the cytoplasm of endothelial cells lining
intra-renal blood vessels including interlobular and arcuate arteries,
arterioles and adjacent arcuate veins, all of which showed strongly positive
staining. JR Big ET-I co-localized with the mature peptide. No specific
staining was detected within these anatomical regions when pEe-immune
sera were substituted or primary antibody omitted. Mature JR ET also
localized to the cytoplasm of endothelial cells within the glomerulus.
Other capillary endothelial cells did not stain, and other structures stained
only faintly by comparison. JR Big ET-2 and Big ET-3 could not be
detected. These results show that human kidney contains mRNA encoding
all three peptide isoforms, but only mature ET and Big ET-l peptides
could be detected by immunocytochemical staining. This provides further
evidence that ET-1 may function as a renal peptide in humans, as it is
locally synthesized within the kidney.
Endothelin-1 (ET-1) is a 21 amino acid peptide [1] thought to
be produced from a 212 residue precursor peptide pre-proET-1
via an intermediate molecule, Big ET-1, which in humans has 38
amino acids [2]. Two further distinct ET genes in humans encode
two other isoforms, ET-2 and ET-3 [3]. Both isoforms are
predicted to be generated via similar intermediate precursors Big
ET-2 (amino acids 1 to 37) and Big ET-3 (1 to 41). Messenger
RNAs for these are thought to be widely distributed in tissues [4].
The endothelins' potent vasoconstrictor action is mediated via
specific G-protein-coupled receptors of two subtypes, ETA and
ETB; in humans this effect is shown by in vitro functional studies
to be mediated predominantly through the ETA subtype [51. In
agreement with this, subtype-selective ligands have shown the
ETA subtype to be mainly on the renal vasculature, whereas ET
occurs on non-vascular structures [6, 7]. Early animal studies
having established the kidney to be exquisitely sensitive to the
vasoconstrictor effects of exogenous ET-1 [8], this organ has
consistently been identified as a candidate for a pathophysiolog-
ical role for this group of peptides. We have previously demon-
strated that human kidney is rich in IR ET-1 by reverse-phase
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high performance liquid chromatography (HPLC) and radioim-
munoassay (RIA) [9]. JR ET is readily detectable in human urine
[10] and the kidney clears ET from the circulation [11]. Cells of
renal origin are stimulated to elaborate ET in culture systems,
including bovine and rat glomerular endothelial [12], human
mesangial [13] and glomerular and tubular epithelial cells [14, 15].
However, it is unclear whether these effects might be induced by
the culture system. Our aim, therefore, was to investigate the local
synthesis of the ET isoforms by polymerase chain reaction (PCR)
amplification of eDNA to establish whether ET may have a
functional role within the kidney. Secondly, we examined by
immunocytochemical localization the cellular distribution of ma-
ture ET and its precursors in the normal human kidney.
Methods
Reagents
Human mature ET and Big ET peptides were obtained from
the Peptide Institute (Osaka, Japan). Swine anti-rabbit antibody,
rabbit peroxidase-antiperoxidase, von Willebrand factor (vWF)
antibody and swine serum came from Dako Ltd. (High Wycombe,
UK). All enzymes were from HT Biotechnology (Cambridge,
UK); dNTPs and oligo-dT came from Pharmacia Ltd. (Milton
Keynes, UK). All other reagents were from Sigma Chemical Co.
(Poole, UK) or Fisons p.l.c. (Loughborough, UK).
Human tissue
Histologically normal renal cortex, medulla, renal artery and
renal vein were obtained at the time of operation from adults (age
range 32 to 74 years) undergoing nephrectomy for non-obstruct-
ing tumors. Tissue was immediately snap-frozen in liquid nitrogen
and stored at —70°C until use. All patients had normal pre-
operative renal function and blood pressure. Adjacent specimens
were examined in the Department of Histopathology which
confirmed the presence of normal parenchymal and vascular
architecture.
Antibodies
Primary antibodies were raised in rabbits to the C-termini of
human ET-1, Big ET-1, Big ET-2 and Big ET-3 as previously
described [16]. As expected from the identity of their C-terminal
sequences, the ET mature peptide antibody showed 100% cross-
reactivity to human ET-1, ET-2 and ET-3, while the three Big ET
antibodies exhibited < 0.01% cross-reactivity with each other or
with mature peptides [17].
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Immunohistochemistiy
Thirty-micrometer thick cross-sections of cortex and medulla
were cut on a cryostat microtome, thaw-mounted onto gelatinized
slides and fixed in 4% wt/vol formaldehyde for 20 minutes at 4°C.
A total of 0.1 M phosphate buffered saline (PBS) was used
throughout for solutions and washes. Sections were then rinsed
twice and blocked for 30 minutes at 20°C with 250 d per slide of
10% swine serum and 0.1% Triton-X100. Sections were then
overlaid with 250 pJ of primary rabbit polyclonal antibody solution
at varying dilutions in the range 1:100 to 1:1000 and containing
1% swine serum, for 24 hours at 4°C. Following two five-minute
washes, they were incubated for one hour at 20°C with 250 j.tl of
1:200 swine anti-rabbit serum. After two further washes, binding
of the primary antibody was visualized using 250 jkl of 1:400 rabbit
peroxidase anti-peroxidase complex for one hour at 20°C, fol-
lowed by 1 ml freshly prepared diaminobenzidine and hydrogen
peroxide solution. Coloration was halted by flooding the slides
with deionized water and sections were dehydrated, cleared in
xylene and DEPEX mounted under glass coverslips. Up to 25
sections were examined from each of five kidneys. Adjacent
sections were stained with an antibody to von Willebrand factor
(vWF), a specific marker for endothelial cells, or with hematoxylin
and eosin. Some sections were also counterstained by immersion
in Mayer's hemalum to facilitate histological identification.
As a positive control ET, Big ET-1 and vWF staining of
cultured endothelial cells from human umbilical vein and artery
were performed. Simultaneous staining of sections of submucosal
glands from normal human lung provided positive controls for Big
ET-2 and Big ET-3. Negative controls were provided by the
substitution of pre-immune sera for each specific immune serum
tested at the same dilutions. No staining was detected when
primary antibodies were preadsorbed with their respective anti-
gens prior to tissue incubation. As a further control, antibodies
were adsorbed with a range of unrelated peptides including
calcitonin gene-related peptide, atrial natriuretic peptide, brady-
kinin and somatostatin (all 1 jIM).
RNA extraction
RNA extraction was performed by a single-step guanidinium
isothiocyanate method [18]. The yield and purity of RNA recov-
ered were determined by optical density determination at 260 and
280 nm. RNA was stored at —70°C.
Reverse transcription
Two g of tissue RNA were annealed to 2 g oligo-dT and
avian myoblastosis reverse transcriptase used for first strand
eDNA synthesis as previously described [19]. cDNA was stored at
—70°C.
Primers
Isoform-specific primers for nested PCR were designed and
used as previously described [19]; their sequences are given in
Table 1. PCR products were cloned and sequenced on both
strands to confirm their identities, including splice variants in the
case of ET-2 and ET-3. Each internal pair included part of the
coding sequence for mature peptide, and all spanned an intron.
PCR assays were performed separately for ET-1, ET-2 and ET-3.
Reagents were mixed at 4°C in 0.5 ml eppendorf tubes under
RNAase-free conditions, such that the final volume per tube was
Table 1. Primer sequences for isoform-specific RT-PCR amplification
of ET cDNAs
Primer Sequence
A ET-1 forward ATGGATTATTTGCTCATGATTTT
(external)
B ET-1 reverse CTTGGGATCATGAAAAGATCATTT
(external)
C ET-2 forward AGCGTCCTCATCTCATGCCC
(external)
D ET-2 reverse TCTCTTCCTCCACCTGGAATG
(external)
E ET-3 forward TCCTTTTCGGGCTCACAGTGA
(external)F ET-3 reverse CTAAGGGGCTCCTTCCTGAAA
(external)
G ET-1,2,3 forward CT (AT) (CT) TGCCAC (CT) TGGACAT
(internal) CAT (TC) TCC
H ET-1 reverse CAGTCTTTCTCCATAATGTCTTCAGC
(internal)
I ET-2 reverse GGCCTCCTGTTGTCGCTTGGCAA
(internal)
J ET-3 reverse GAGGCAGCGGGGGCAGGTAGAT
(internal)
29 jIl, in the following concentrations: 1 X PCR buffer, 200 jIM
dNTPs, 1 m appropriate primer pairs, and 1.5 U Taq DNA
polymerase. For the first round, 1 pi of template eDNA was added
to each tube as the last step. For the second round, I pA of first
round product provided the template. Each was overlaid with
mineral oil and amplification carried out on a Hybaid Omnigene
programmable thermocycler, preheated to 95°C. PCR profiles
were as follows: 95°C 1.5 minutes; primers A-F: [95°C 0.5
minutes, 63°C 0.5 minutes, 72°C 0.5 minutes] X 25 cycles; primers
G-J: [95°C 0.5 minutes, 72°C 1.0 minutes] X 25 cycles; 72°C three
minutes.
Products were electrophoresed in 1% ethidium bromide-
stained agarose gels and bands visualized under ultraviolet light.
Results
Immunostaining for mature ET
Intense staining of the cytoplasm of endothelial cells lining
intra-renal blood vessels including interlobular and arcuate arter-
ies, arterioles and adjacent arcuate veins was detected using the
antisera directed against mature JR ET in multiple sections of all
the kidneys examined. Capillary endothelia did not show specific
staining. Mature JR ET also localized to intraglomerular endo-
thelial cells, as shown in Figure 1. Specificity of these appearances
was confirmed by the absence of staining when pre-immune sera
were substituted, and by the persistence of positive staining when
sera in the presence of unrelated peptides were employed.
Identical positive staining with vWF antibody of adjacent sections
confirmed the endothelial origin of ET-containing cells and
showed the specific staining to be confined to vessels where
smooth muscle was present, as shown in Figure 1. There was no
evidence of IR ET staining of the smooth muscle itself. At low
antibody dilution (1:200), some staining of tubular epithelia was
observed. However, this appearance was not seen at higher
dilutions and was always significantly weaker than vascular endo-
thelial immunoreactivity.
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five arteries and one of five veins were positive, and in only a
single artery was ET-3 mRNA demonstrable. These gel images
are shown in Figure 3.
Discussion
Fig. 1. Brightjield photomicrograph showing an example of the presence of
(A) JR ET and (B) von Willebrand factor in the cytoplasm of endothelial cells
in the glomerulus (g) and an adjacent resistance vessel (v) in human kidney.
Sections were incubated with primary antisera and binding visualised using
the peroxidase-antiperoxidase technique. Substitution of pre-immune
anti-ET antisera or preadsorption with mature ET peptides resulted in
absence of staining.
Immunostaining for Big ET isoforms
JR Big ET-1 co-localized with the mature peptide immunore-
activity. Again the substitution of the relevant pre-immune sera
resulted in the absence of staining. No specific staining was
observed using antisera to Big ET-2 or Big ET-3 in any of the
specimens examined.
RT-PCR
Products corresponding to the expected sizes for mRNA en-
coding all three isoforms ET-1, ET-2 and ET-3 were visualized
following RT-PCR assay of renal medulla and cortex from each of
five individuals. ET-1 and ET-2 mRNA were present in all
samples, with ET-3 mRNA being detectable in four of the five
medullas and two of the five cortices. A representative series of
agarose gels is shown in Figure 2. In the case of ET-1, the extra
bands seen were shown by cloning and sequencing to correspond
to the products of heminesting. For ET-2 and ET3, any extra
bands seen corresponded to the position of known splice variants
[19]. RT-PCR assay of five pairs of extra-renal artery and vein
demonstrated mRNA for ET-1 in all, but for ET-2, only two of
The use of nested RT-PCR as described here confirmed that
both renal parenchymal tissue and main renal artery and vein
contain mRNA for ET-1. This result, together with the previous
positive identification of IR ET-1 by HPLC and RIA [9] and
positive immunostaining as described, provide strong evidence for
local synthesis of ET-1 by endothelial cells in the kidney and its
vasculature in cx vivo tissue.
Jmmunocytochemical staining of histologically normal tissue
localized mature ET to endothelial structures of arteriolar calibre
and larger, together with intraglomerular capillary endothelium.
At high power this staining was visible in the cytoplasm, with
nuclear sparing, the appearances of sections stained with von
Willebrand factor being essentially identical. The presence of IR
Big ET-1 at the same sites also suggests local synthesis. This
localization would support the proposal that ET has a vasoactive
action within the kidney, as in the vasculature itself, especially
given the presence of ETA receptors on the renal vascular smooth
muscle [6] and the potency of ET-1 in constricting renal vessels via
this receptor subtype in vitro [20].
Staining was not observed either in smooth muscle of the vessel
wall or in mesangial cells. The former is in agreement with
Howard, Plumpton and Davenport [211 where IR ET was found in
the cytoplasm of endothelial but not smooth muscle cells in
cross-sections of a range of human vessels. However, it has been
previously shown that vascular smooth muscle cells in culture are
capable of elaborating both ET-1 and ET-3 [22], suggesting that
culture systems may not always reflect the in vivo situation and
possibly that ET isoform synthesis may be inducible in pathophys-
iological circumstances. Mesangial cells have been reported to
secrete IR ET in culture [13]. While we cannot exclude the
possibility that these cells have the capacity to do this in the intact
kidney, the pattern of staining with antibodies to mature ET and
to the endothelial cell marker vWF were very similar, suggesting
that most of the ET was endothelial in origin. At the light
microscope level we could not detect any obvious staining of
mesangial cells even at low antibody dilution, which suggests very
low levels (if any) of ET synthesis by these cells in vivo. Dual
staining at the electron microscope level might be required to
resolve this speculation.
The well-recognized species differences in the ET system have
directed our efforts to study human tissue. The immunocytochem-
ical appearances reported here are in agreement with a brief
report from Susin et al [23], with intense staining (compared to
pre-immune control sera) using antibodies to mature ET in
vascular and glomerular endothelium. However, a recent study by
Ong et al [24J observed more prominent tubular staining. The
reason for this discrepancy is intriguing. Isolating cells in culture
may induce them to secrete ET, which may also occur under
pathophysiological conditions. In our study we have used histo-
logically and functionally normal tissue from the opposite pole to
tumour, whereas Ong et al employed renal biopsy material from
individuals with microscopic haematuria. Thus, in the former
study cells were not producing ET in sufficient amount to be
detected, whereas in the latter study it is possible that these cells
had been induced to synthesize ET. A second possibility is that of
—+ 109876 54321 M
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432 bp
C 3lObp(ET-2)
211 bp
88 bp
tE
405 bp
370 bp (ET-3)
324 bp
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Fig. 2. Representative agarose gels showing
products of PCR amplification of human renal
parenchyma eDNA with ET-1-, ET-2- and ET-3-
specific primers. Lanes 1 to 5, medulla; 6 to 10,
cortex; +, positive control (HUVEC for ET-1,2
and placenta for ET-3); —, negative control(template omitted). Marker lane = 100 bp
ladder. Arrows indicate the positions of known
splice variants.
tubular reuptake of filtered ET. Thirdly, there may be differences
in the cross reactivities of the antibodies used. Our antibodies
have been extensively characterized [16, 17, 21], which is necessary
in part because of the high degree of homology between the
different ET isoforms. They have also been tested for absence of
cross reactivity to a wide variety of other peptides. In addition,
technical differences exist between investigators.
Interestingly, RT-PCR showed frequent occurrence of ET-2
and to a lesser extent ET-3 mRNA. O'Reilly et al have shown
ET-2 mRNA to be present in human amnion, chorion, left
ventricle, cultured human vascular smooth muscle and human
umbilical vein endothelial cells (HUVEC) [19], and both ET-2
and ET-3 mRNAs in endometrium [25]. They have not previously
been identified in human kidney. ET-2 mRNA was found in
almost every sample of renal tissue. Although ET-3 mRNA was
often present in normal kidney, both were markedly less frequent
in samples of renal artery and vein, with only two arteries and one
vein positive for ET-2 and one artery for ET-3 from a total of five
pairs examined. The significance of any differences in expression
between kidney and vessels is not clear.
The high sensitivity of RT-PCR permitted detection of mRNA
for all three isoforms, specificity being ensured by the use of
nested primers, whereas HPLC and RIA identified only the ET-1
and oxidized peptide isoform. This suggests ET-1 to be the
predominant isoform in the kidney. It is possible that ET-2 and
ET-3 are expressed at a level too low for detection by HPLC/RIA.
Similar reasoning applies to Big ET-1, particularly in the light of
the finding that the amount of Big ET-1 secreted by HUVECs is
an order of magnitude less than that of mature ET [26]. There are
two further possible explanations for the apparent discrepancy
between RT-PCR and peptide findings. The first is that because
the PCR actually amplifies eDNA for preproETs, the mature
peptide being a post-translational product of preproET cleavage,
there may be a failure of translation of preproET-2 and -3 which
does not occur with ET-1. However, the observed presence of 3'
regulatory sequences in the human ET genes [2, 27] has as yet not
been further characterized. Secondly, post-translational events
might differ between the isoforms such that in the kidney only
ET-1 is produced. The recent characterization of isoforms for the
first human endothelin converting enzyme (ECE-1), where
ECE-la preferentially cleaved Big ET-1 [28], supports this hy-
pothesis. It is difficult to know what significance to ascribe to these
12 11 10 9 8 7 6 5 4 3 2 1
i— 222 bp(ET-1)
— 310 bp (ET.2)
'—• 370 bp(ET-3)
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Fig. 3. Representative agarose gels showing
products of PCR amplification of human renal
vessel cDNA with ET-1-, ET-2- and ET-3 -specific
primers. Lanes 2 to 5, renal artery; 8 to 11,
renal vein; 6, positive control; 7, negative
control (template omitted); 1, 12, 100 bp
ladder.
findings, not only because so little functional information is
available with respect to the human kidney, but also because,
although there are many precedents for failure to translate
mRNA into peptide, particularly in fetal tissues, it is not known
what physiological purpose would be served by such a phenome-
non in the kidney.
Previous studies in rats, pigs and humans have shown the inner
medulla of the kidney to be rich in JR ET [29—31]. However,
although the presence of JR ET in human urine has been readily
detectable [10] and both rat and pig kidneys have been shown by
Northern bJot analysis, in situ hybridization and RNAase protec-
tion assay to contain mRNA for ET [4, 321, the coexistence of
peptide and message have not previously been demonstrated in
human renal tissues. From the studies presented here, the human
kidney becomes established as more than simply an excretory
organ for ET, by the demonstration of messenger RNA for ET
isoforms using nested RT-PCR together with identification of JR
ET and Big ET-1 and its localization by immunocytochemical
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staining. This combination of synthetic activity with mature pep-
tide suggests that ET may play a functional role in human kidney,
that is, human kidney represents a source of as well as a sink for
endogenous ET.
In summary, the studies performed here to establish ET as a
renal peptide in humans show the presence for ET-1 of both
peptide and mRNA in parenchyma and vessels, implying local
synthesis. For ET-2 and ET-3, mRNA but no detectable peptides
were found. In addition, JR ET was localized principally to
endothelial structures within the kidney.
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